| BIIB094 / Ionis, Biogen |
NCT03976349: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease |
|
|
| Completed | 1 | 82 | Europe, Canada, US, RoW | BIIB094, Placebo | Biogen, Ionis Pharmaceuticals, Inc. | Parkinson's Disease | 08/24 | 08/24 | | |
| DNL151 / Denali Therap, Biogen |
2022-000747-77: A Study to Assess if BIIB122 Tablets are Safe and can Slow Worsening of Early-Stage Parkinson's Disease in Participants with Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale |
|
|
| Not yet recruiting | 3 | 400 | Europe | BIIB122, DNL151, Tablet | Biogen Idec Research Limited, BIOGEN IDEC RESEARCH LIMITED, Biogen Idec Research Limited | Parkinson's Disease, Parkinson's Disease, Diseases [C] - Nervous System Diseases [C10] | | | | |
LIGHTHOUSE, NCT05418673: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale |
|
|
| Terminated | 3 | 7 | Europe, US | BIIB122, DNL151, BIIB122-Matching Placebo | Biogen, Denali Therapeutics Inc. | Parkinson Disease | 07/23 | 07/23 | | |
2021-004849-20: A Study to Assess the Safety of BIIB122 Tablets and if it can Slow the Worsening of Early-Stage Parkinson’s Disease in Participants Between the Ages of 30 and 80 |
|
|
| Not yet recruiting | 2 | 640 | Europe | BIIB122, DNL151, DN0001575, DN1575, Tablet | Biogen Idec Research Limited, BIOGEN IDEC RESEARCH LIMITED, Biogen Idec Research Limited | Parkinson's Disease, Parkinson's Disease, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT06602193: Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) |
|
|
| Recruiting | 2 | 50 | US | BIIB122 225 mg, DNL151, BIIB122-Matching Placebo | Denali Therapeutics Inc., Biogen | Parkinson Disease | 04/26 | 02/28 | | |
LUMA, NCT05348785: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 |
|
|
| Recruiting | 2 | 640 | Europe, Canada, Japan, US, RoW | BIIB122, DNL151, BIIB122-Matching Placebo | Biogen, Denali Therapeutics Inc. | Parkinson Disease | 12/25 | 12/25 | | |
NCT06264440: A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants |
|
|
| Completed | 1 | 18 | US | BIIB122, DNL151, Rabeprazole | Biogen | Healthy Volunteer | 06/24 | 06/24 | | |
| H-1337 / D. Western Therapeutics Institute |
NCT05913232: Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension |
|
|
| Completed | 2 | 201 | US | H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5% | D. Western Therapeutics Institute, Inc. | Glaucoma Open-Angle Primary, Ocular Hypertension | 08/24 | 08/24 | | |
NCT06572397: Open-Label Study of Safety of H1337 in Healthy Volunteers |
|
|
| Completed | 1 | 17 | US | H-1337 1.0% | D. Western Therapeutics Institute, Inc. | Glaucoma Open-Angle Primary, Ocular Hypertension | 10/24 | 10/24 | | |
| FB418 / 1ST Bio |
NCT05995782: A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 |
|
|
| Not yet recruiting | 1 | 64 | NA | FB418, FB418 active drug | 1ST Biotherapeutics, Inc. | Parkinson Disease Psychosis, Amyotrophic Lateral Sclerosis (ALS) | 09/24 | 12/24 | | |
| NEU-723 / Neuron23 |
NCT05633745: A Study to Assess NEU-723 in Healthy Participants |
|
|
| Terminated | 1 | 40 | RoW | NEU-723, Placebo | Neuron23 Inc. | Healthy | 06/23 | 06/23 | | |
| NEU-411 / Neuron23 |
NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson's Disease |
|
|
| Not yet recruiting | 2 | 150 | NA | NEU-411, Placebo | Neuron23 Inc. | Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic | 09/26 | 09/27 | | |
NCT05755191: A Study to Assess NEU-411 in Healthy Participants |
|
|
| Completed | 1 | 147 | RoW | NEU-411, Placebo | Neuron23 Inc. | Healthy | 06/24 | 06/24 | | |
